Form 4: Tharimmune Executive Chairman Granted 90,000 Stock Options

Tharimmune's Executive Chairman, Vincent S LoPriore, was granted 90,000 stock options with an exercise price of $3.075, effective November 3, 2025.

Summary

• Vincent S LoPriore, Executive Chairman, Director, and 10% Owner of Tharimmune, Inc. (THAR), was granted 90,000 stock options.
• The stock options have an exercise price of $3.075 per share.
• The transaction is scheduled to occur on November 3, 2025, and the options become exercisable on the same date.
• The options are set to expire on November 3, 2035.
• This transaction was made pursuant to a Rule 10b5-1(c) plan, indicating a pre-arranged future transaction.
• Following this grant, Mr. LoPriore will beneficially own a total of 190,000 derivative securities.

Sentiment

Score: 6

Explanation: Neutral to slightly positive. The grant of options is a standard compensation practice that aligns executive interests with shareholders, but it's not a direct indicator of immediate operational success or financial performance. The future-dated transaction under a 10b5-1 plan is a procedural detail.

Positives

• The grant of stock options aligns management's long-term interests with shareholder value creation.
• The options have a 10-year expiration period, providing a substantial long-term incentive for the executive.

Negatives

• No immediate cash inflow for the company from the grant itself, as the derivative security price is $0.
• Potential future dilution for existing shareholders if the options are exercised.

Risks

• If the company's stock price does not appreciate above the exercise price of $3.075, the options may become worthless.
• Future exercise of these and other outstanding options could lead to dilution of existing shareholders' equity.

Future Outlook

The grant of stock options to a key executive indicates a long-term incentive strategy, aligning management's future performance with shareholder returns over the next decade, contingent on the company's stock price appreciating above the exercise price.

Industry Context

Stock option grants are a common form of executive compensation in the biotechnology and pharmaceutical industries, particularly for companies in development stages. They serve to incentivize long-term value creation and retain key talent, aligning executive interests with company growth.

Comparison to Industry Standards

• Granting stock options with a 10-year term is standard practice for executive compensation in many growth-oriented industries, including biotech, to encourage long-term commitment and performance.
• The exercise price being set at the market price on the grant date (implied by the $0 derivative price) is typical for incentive stock options.

Corporate Governance

Stakeholder Impact

• Shareholders: Potential for increased long-term value if the options incentivize strong company performance; potential for minor dilution upon exercise.
• Management: Provides a significant long-term incentive tied to stock price appreciation.

Next Steps

• Monitoring the company's stock performance relative to the $3.075 exercise price.
• Future SEC filings will report any exercise or sale of these options by the executive.

Key Dates

Recommendation

This Form 4 reports a routine, pre-planned grant of stock options to an executive, which is a standard compensation practice. It does not provide new information about the company's operational performance, financial health, or strategic direction that would warrant a change in investment recommendation. The transaction aligns executive incentives with long-term shareholder value, which is generally positive, but does not fundamentally alter the investment thesis.

Keywords

Tharimmune, THAR, Stock Options, Executive Compensation, Form 4, Insider Transaction, Vincent S LoPriore, Equity Grant, 10b5-1 Plan